Analysis of effects of bosentan (Ro 47-0203), a nonpeptide endothelin ET(A)/ET(B) receptor antagonist, in the hind-limb vascular bed of the cat

Canadian Journal of Physiology and Pharmacology

Volumn 76, Issue 2, 1998, Pages 141-147

  Champion, Hunter C ^a   Estrada, Lance S ^a   Estrada, Leslie N ^a   Filep, Janos G ^b   Kadowitz, Philip J ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

Angiotensin II; Bosentan (Ro 47 0203); Endothelial derived peptide; Endothelin; Regional vascular bed

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; 1,4 DIHYDRO 2,6 DIMETHYL 5 NITRO 4 [2 (TRIFLUOROMETHYL)PHENYL] 3 PYRIDINECARBOXYLIC ACID METHYL ESTER; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; 4 PENTAFLUOROETHYL 2 PROPYL 1 [[2' (1H TETRAZOL 5 YL)BIPHENYL 4 YL]METHYL] 5 IMIDAZOLECARBOXYLIC ACID; ACETYLCHOLINE; ADRENOMEDULLIN; ANGIOTENSIN; ARGIPRESSIN; BOSENTAN; BRADYKININ; CALCITONIN GENE RELATED PEPTIDE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN B RECEPTOR; LEMAKALIM; NORADRENALIN; PROSTAGLANDIN E1; SARAFOTOXIN S6C;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; BLOOD VESSEL TONE; CAT; CONTROLLED STUDY; DRUG ANTAGONISM; HINDLIMB; NONHUMAN; PERFUSION PRESSURE; PRIORITY JOURNAL; VASOCONSTRICTION; VASODILATATION;

ANGIOTENSIN II; ANIMALS; ANTIHYPERTENSIVE AGENTS; CATS; ENDOTHELIN-1; HINDLIMB; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; SULFONAMIDES; VASOCONSTRICTION; VASODILATION; VASOPRESSINS;

EID: 0031780362     PISSN: 00084212     EISSN: None     Source Type: Journal    
DOI: 10.1139/cjpp-76-2-141     Document Type: Article

References (30)

1. Bakris, G.L., and Re, R.N. 1993. Endothelin modulates angiotensin II-induced mitogenesis of human mesangial cells. Am. J. Physiol. 264: F937-F942.
2. Balakrishnan, S.M., Wang, H.D., Golpalakrishnan, V., Wilson, T.W., and McNeill, J.R. 1996. Effect of an endothelin antagonist on hemodynamic responses to angiotensin II. Hypertension, 28: 806-809.
3. Barnes, P.J. 1994. Endothelins and pulmonary diseases. J. Appl. Physiol. 77: 1051-1059.
4. Chen, L., McNeill, J.R., Wilson, T.W., and Gopalakrishnan, V. 1995a. Heterogeneity in vascular smooth muscle responsiveness to angiotensin II: role of endothelin. Hypertension, 26: 83-88.
5. Chen, L., McNeill, J.R., Wilson, T.W., and Gopalakrishnan, V. 1995b. Differential effects ofphosphoramidon on contractile responses to angiotensin II in rat blood vessels. Br. J. Pharmacol. 114: 1599-1604.
6. Clozel, M., Breu, V., Gray, G.A., Kalina, B., Loffler, B.-M., Burn, K., Cassai, J.-M., Hirth, G., Muller, M., Neidhart, W., and Ramuz, H. 1994. Pharmacological characterization of bosentan, a new potent orally active non-peptide endothelin receptor antagonist. J. Pharmacol. Exp. Ther. 270: 2218-2235.
7. Dohi, Y., Hahn, A.W.A., Boulanger, C.M., Buhler, F.R., and Luscher, T.F. 1992. Endothelin stimulated by angiotensin II augments contractility of spontaneously hypertensive rat resistance arteries. Hypertension, 19: 131-137.
8. Filep, J.G., Clozel, M., Fournier, A., and Foldes-Filep, E. 1994. Characterization of receptors mediating vascular responses to endothelin-1 in the conscious rat. Br. J. Pharmacol. 113: 845-852.
9. B receptors. Br. J. Pharmacol. 115: 227-236.
10. B receptor antagonist, bosentan on endothelin-1-induced myocardial ischaemia and oedema in the rat. Br. J. Pharmacol. 116: 1745-1750.
11. B-receptor antagonist, on regional haemodynamic responses to endothelins in conscious rats. Br. J. Pharmacol. 112: 823-830.
12. Garrison, E.A., Santiago, J.A., Osei, S.Y., and Kadowitz, P.J. 1995. Analysis of rtepsonses to angiotensin peptides in the hindquarters vascular bed of the cat. Am. J. Physiol. 268: H2418-H2425.
13. Imai, T., Hirata, Y., Emori, T., Yanagisawa, M., Masaki, T., and Marumo, F. 1992. Induction ofendothelin-1 gene by angiotensin and vasopressin in endothelial cells. Hypertension, 19: 753-757.
14. Inoue, A., Yanagisawa, M., Imura, S., Kasuya, Y., Miyauchi, T., Goto, K., and Masaki, T. 1989. The human endothelin family: three structurally and pharmacologically distinct isopeptides predicted by three separate genes. Proc. Natl. Acad. Sci. U.S.A. 86: 2863-2867.
15. Ishida, N., Tsujioka, K., Tomoi, M., Saida, K., and Mitusi, Y. 1989. Differential activities of two distinct endothelin family peptides on ileum and coronary artery. FEBS Lett. 247: 337-340.
16. Kiowski, W., Sutsch, G., Hunziker, P., Muller, P., Kim, J., Oechslin, E., Schmitt, R., Jones, R., and Betel, O. 1995. Evidence for endothelin-1-mediated vasoconstriction in severe chronic heart failure. Lancet, 346: 732-736.
17. Kloog, Y., Ambar, I., Sokolovsky, M., Kochva, E., Wollberg, Z., and Bdolah, A. 1988. Sarafotoxin, a novel vasoconstrictor peptide: phosphoinositide hydrolysis in rat heart. Science (Washington, D.C.), 242: 268-270.
18. Lerman, A., Hildebrand, F.L., Aarhus, L.L., and Burnett, J.C. 1991. Endothelin has biological actions at pathological concentrations. Circulation, 83: 1808-1814.
19. Levin, E. 1995. Endothelins. N. Engl. J. Med. 333: 356-363.
20. Minkes, R.K., MacMillan, L.A., Bellan, J.A., Kerstein, M.D., McNamara, D.B., and Kadowitz, P.J. 1989. Analysis of responses to endothelin in the hindquarters vascular bed of the cat. Am. J. Physiol. 256: H598-H602.
21. Minkes, R.K., Bellan, J.A., Higuera, T.R., and Kadowitz, P.J. 1992. Comparison of responses to sarafotoxins 6a and 6c in pulmonary and systemic vascular beds. Am. J. Physiol. 262: H852-H861.
22. Osei, S.Y., Minkes, R.K., Bellan, J.A., and Kadowitz, P.J. 1993. Analysis of inhibitory effects of DuP 753 and Exp 3174 on responses to angiotensin II in the feline hindquarters vascular bed. J. Pharmacol. Exp. Ther. 264: 1104-1112.
23. Pacher, R., Bergler-Klein, J., and Globits, S. 1993. Plasma big endothelin-1 concentrations in congestive heart failure patients with or without systemic hypertension. Am. J. Cardiol. 71: 1293-1299.
24. Sokolovsky, M. 1992. Endothelins and sarafotoxins: physiological regulation, receptor subtypes and transmembrane signalling. Pharmacol. Ther. 54: 129-149.
25. Teerlink, J.R., Loffler, B.M., Hess, P., Maire, J.P., Clozel, M., and Clozel, J.P. 1994. Role of endothelin in the maintenance of blood pressure in conscious rats with chronic heart failure. Acute effects of the endothelin receptor antagonist Ro 47-0203 (bosentan). Circulation, 90: 2510-2518.
26. Teerlink, J.R., Carteaux, J.P., Sprecher, U., Loffler, B.M., Clozel, M., and Clozel, J.P. 1995. Role of endogenous endothelin in normal hemodynamic status of anesthetized dogs. Am. J. Physiol. 268: H432-H440.
27. Veniant, M., Clozel, J.P., Hess, P., and Clozel, M. 1994. Endothelin plays a role in the maintenance of blood pressure in normotensive guinea pigs. Life Sci. 55: 445-454.
28. Watanabe, T., Suzuki, N., Shimamoto, N., Fujino, M., and Imada, A. 1990. Endothelin in myocardial infarction. Nature (London), 344: 114-117.
29. Webb, M.L., Dickinson, K.E.J., Delaney, C.L., Liu, E.C.K., Serafino, R., Cohen, R.B., Monshizadegan, H., and Moreland, S. 1992. The endothelin receptor antagonist, BQ-123, inhibits angiotensin II-induced contractions in rabbit aorta. Biochem. Biophys. Res. Commun. 185: 887-892.
30. Yanagisawa, M., Kurihara, H., Kimura, S., Tomobe, Y., Kobayashi, M., Mitsui, Y., Yazaki, Y., Goto, K., and Masaki, T. 1988. A novel potent vasoconstrictor peptide produced by vascular endothelial cells. Nature (London), 332: 411-415.